X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (401) 401
female (280) 280
index medicus (235) 235
phthalazines - therapeutic use (230) 230
male (214) 214
middle aged (201) 201
adult (198) 198
phthalazines - adverse effects (197) 197
phthalazines - administration & dosage (193) 193
aged (144) 144
oncology (128) 128
phthalazines - pharmacology (104) 104
treatment outcome (96) 96
animals (84) 84
double-blind method (81) 81
pharmacology & pharmacy (76) 76
piperazines - therapeutic use (76) 76
cancer (74) 74
antineoplastic agents - therapeutic use (73) 73
piperazines - adverse effects (72) 72
adolescent (71) 71
rhinitis, allergic, seasonal - drug therapy (70) 70
administration, intranasal (68) 68
ovarian neoplasms - drug therapy (65) 65
poly polymerase (63) 63
chemotherapy (60) 60
mutation (59) 59
piperazines - administration & dosage (58) 58
azelastine (56) 56
ovarian cancer (56) 56
allergy (53) 53
olaparib (52) 52
phthalazines - pharmacokinetics (52) 52
care and treatment (47) 47
dose-response relationship, drug (47) 47
ovarian neoplasms - genetics (47) 47
histamine h1 antagonists - therapeutic use (46) 46
tumors (46) 46
antineoplastic agents - adverse effects (44) 44
breast cancer (44) 44
piperazines - pharmacology (43) 43
aged, 80 and over (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (42) 42
mice (42) 42
analysis (41) 41
child (40) 40
safety (39) 39
histamine h1 antagonists - administration & dosage (38) 38
immunology (38) 38
poly polymerase inhibitors (38) 38
allergic rhinitis (37) 37
dna repair (37) 37
double-blind (37) 37
rhinitis, allergic, perennial - drug therapy (37) 37
anti-allergic agents - therapeutic use (36) 36
administration, oral (35) 35
poly polymerase inhibitors - therapeutic use (35) 35
disease-free survival (34) 34
histamine h1 antagonists - adverse effects (34) 34
neoplasms - drug therapy (34) 34
brca1 protein - genetics (33) 33
brca2 protein - genetics (33) 33
efficacy (33) 33
open-label (33) 33
inhibition (32) 32
research (32) 32
therapy (32) 32
angiogenesis (31) 31
drug therapy (31) 31
pyridines - administration & dosage (31) 31
young adult (31) 31
homologous recombination (30) 30
anti-allergic agents - administration & dosage (29) 29
cancer therapies (29) 29
cell line, tumor (29) 29
deoxyribonucleic acid--dna (29) 29
medicine & public health (29) 29
ovarian neoplasms - pathology (29) 29
antineoplastic agents - pharmacology (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (28) 28
bevacizumab (28) 28
drug administration schedule (28) 28
medicine, general & internal (28) 28
poly polymerase inhibitors - adverse effects (28) 28
antineoplastic agents - administration & dosage (27) 27
clinical trials as topic (27) 27
pyridines - therapeutic use (27) 27
breast neoplasms - drug therapy (26) 26
clinical trials (26) 26
genetic aspects (26) 26
maximum tolerated dose (26) 26
ovarian-cancer (25) 25
maintenance therapy (24) 24
pyridines - adverse effects (24) 24
asthma (23) 23
endothelial growth-factor (23) 23
genes, brca1 (23) 23
genes, brca2 (23) 23
neoplasm recurrence, local - drug therapy (23) 23
patients (23) 23
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (433) 433
French (5) 5
Japanese (3) 3
German (2) 2
Russian (2) 2
Spanish (2) 2
Hungarian (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 6, pp. 523 - 533
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 18, pp. 1697 - 1708
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3, pp. 244 - 250
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 852 - 861
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 852 - 861
Summary Background Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | BRCA2 MUTATIONS | LIPOSOMAL DOXORUBICIN | RIBOSE POLYMERASE INHIBITORS | SOLID TUMORS | ONCOLOGY | GENETICS | GUIDELINES | SENSITIVITY | RESISTANCE | PARP INHIBITOR | Humans | Middle Aged | Ovarian Neoplasms - pathology | Carcinoma - mortality | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Time Factors | Aged, 80 and over | Cell Differentiation | Carcinoma - drug therapy | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Administration, Oral | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Canada | Breast Neoplasms - genetics | Carcinoma - genetics | Mutation | Receptor, ErbB-2 - analysis | Piperazines - administration & dosage | Receptors, Estrogen - analysis | Ovarian Neoplasms - mortality | Breast Neoplasms - enzymology | Antineoplastic Agents - adverse effects | Carcinoma - enzymology | Adult | Female | Ovarian Neoplasms - drug therapy | Carcinoma - secondary | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Treatment Outcome | BRCA1 Protein - genetics | Disease-Free Survival | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | BRCA2 Protein - genetics | Phthalazines - adverse effects | Care and treatment | Relapse | Gene mutations | Oncology, Experimental | Breast cancer | Research | Cancer | Diseases | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2012, Volume 18, Issue 8, pp. 2344 - 2351
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 6, pp. dju089 - dju089
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2018, Volume 379, Issue 8, pp. 753 - 763
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 15, pp. 1382 - 1392
Journal Article